期刊文献+

不同时间段给予替米沙坦治疗高血压的临床疗效及安全性分析

Different Time Periods Given Telmisartan Treatment of Hypertension Clinical Efficacy and Safety Analysis
下载PDF
导出
摘要 目的:探究与分析不同时间段给予替米沙坦治疗高血压的临床疗效及安全性。方法:选取本院2012年12月-2014年12月收治的60例高血压患者,采取随机数字表法分为早间服药组与晚间服药组,每组各30例,早间服药组于每天早8∶00点服用替米沙坦,晚间服药组于每天晚20∶00点服用替米沙坦,对比两组患者的临床疗效。结果:早间服药组总有效率为90.00%,晚间服药组总有效率为93.33%,两组比较差异无统计学意义(字2=1.78,P>0.05)。早间服药组与晚间服药组白天收缩压与舒张压平均值比较,差异无统计学意义(P>0.05);但夜间比较差异有统计学意义(P<0.05);两组24 h收缩压与舒张压平均值比较,差异亦无统计学意义(P>0.05)。早间服药组恶心、头晕、头痛发生率分别为10.00%、16.67%、13.33%,晚间服药组恶心、头晕、头痛发生率分别为6.67%、13.33%、10.00%,两组比较差异无统计学意义(P>0.05)。结论:两种服用方法均可对高血压患者的血压产生影响,但晚间服药疗效明显优于早间服药,值得推广与应用。 Objective: To explore and analyze different time periods given telmisartan treatment of hypertension clinical efficacy and safety. Method: In our hospital from December 2012 to Deeember 2014 60 eases hypertensive patients were selected and divided into morning medication group and evening medication group, 30 eases in each group. Morning medication group took telmisartan at 8 : 00 am, and evening medication group took telmisartan at 8 : 00 pm. To compare curative effect between the two groups. Result: The total effective rate of the morning medication group was 90.00%, and that of the evening medication group was 93.33%, with no significant difference between the two groups ( x^2=1.78, P〉0.05 ) . Systolic and diastolic blood pressure between the two groups showed no significant difference during daytime and 24 h, but had at night. Nausea, dizziness, headache rate of the morning medication group was 10.00%, 16.67%, 13.33%, and that of the evening medication group was 6.67%, 13.33%, 10.00%, there was no significant difference between the two groups (P〉0.05) . Conclusion: Both methods can take effect on blood pressure in hypertensive patients, but clinical efficacy in the evening for hypertensive patients taking telmisartan was significantly better than the morning medication, worthy of promotion and application.
作者 张翠荣
出处 《中国医学创新》 CAS 2015年第25期47-49,共3页 Medical Innovation of China
关键词 替米沙坦 高血压 疗效 安全性 不同时间 Telmisartan Hypertension Efficacy Safety Different times
  • 相关文献

参考文献15

  • 1田相亭,黄平.伊贝沙坦对老年原发性高血压患者血管内皮功能的影响[J].中华老年医学杂志,2005,24(4):262-265. 被引量:9
  • 2刘力生,龚兰生,胡大一,等.中国高血压防治指南[J].高血压杂志,2005,13(12):10-11.
  • 3何义霞.替米沙坦治疗原发性高血压的临床疗效观察[J].大家健康(学术版),2014(13):106-107. 被引量:5
  • 4Kakuta H, Sodoh K, Sasamata M, et al. Telmisartan has the stronge binding affinity to angiotensin ]I type 1 receptor: comparison with other angiotensin lI type receptor blockers[J]. Int J Clin Pharmacol Res, 2012, 25 (1):41-46.
  • 5Schillaci G, Pucci G, Parati G. Blood pressure variability: an additional target for antihypertensive treament[J]. Hypertension, 2011, 58 (2): 3133-3135.
  • 6Auler JO Jr, Galas F R, Sundin M R, et al. Arterial pulse pressure variation predicting fluid responsiveness in critically ill patitents[J]. Shoek, 2012, 30 (2): 2118-2122.
  • 7杨萌,王显良,李波,蔡瑞艳.130例原发性高血压患者临床治疗与观察[J].中国医学创新,2014,11(6):91-93. 被引量:10
  • 8Mourad J, Waeder B, Zinnad F. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perinodopril/ indapamide versus a sequential monotherapy or a stepped-care apporach[J]. J Hypertens, 2014, 23 ( 22 ) .. 2379-2380.
  • 9孔祥阳,牛麦玲.波依定治疗原发性高血压病30例的疗效观察[J].中国医学创新,2012,9(26):113-114. 被引量:5
  • 10Huang Chunfa Louis Stokes Cleveland Veteran Affairs Medical Center,Division of Nephrology,Departments of Medicine,Case Western Reserve University,and Rammelkamp Center for Research and Education,MetroHealth System Campus,Cleveland,Ohio 441061.Hypertension and renal disease[J].中华高血压杂志,2011,19(12):1116-1119. 被引量:24

二级参考文献83

  • 1陈建华,蔡卓珊.硝苯地平缓释片治疗老年人原发性高血压疗效观察[J].海南医学,2006,17(5):80-81. 被引量:22
  • 2冯琳,侯孝云,孟玲,戴惠珍,陶琳.2005年长江流域157家医院心血管系统药物利用分析[J].中国新药与临床杂志,2007,26(3):175-179. 被引量:17
  • 3Ritz E.Hypertension and kidney disease[J].Clin Nephrol,2010,74(suppl1):S39-43.
  • 4Bakris GL,Ritz E.The message for world kidney day2009:hypertension and kidney disease:a marriage that should be prevented[J].Kidney Int,2009,75(5):449-452.
  • 5Toto RD.Treatment of hypertension in chronic kidney disease[J].Semin Nephrol,2005,25(6):435-439.
  • 6Hsu CY,McCulloch CE,Darbinian J,et al.Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease[J]Arch Intern Med,2005,165(8):923-928.
  • 7Brantsma AH,Bakker SJ,de Zeeuw D,et al.Urinary albumin excretion as a predictor of the development of hypertension in the general population[J]J Am Soc Nephrol,2006,17(2):331-335.
  • 8Pavenstadt H,Kriz W,Kretzler M.Cell biology of the glomerular podocytes[J].Physiol Rev,2003,83(1):253-307.
  • 9Comper WD,Russo LM.The glomerular filter:an imperfect barrier is required for perfect renal function[J].Curr Opin Nephrol Hypertens,2009,18(4):336-342.
  • 10Endlich N,Kress KR,Reiser J,et al.Podocytes respond to mechanical stress in vitro[J].J Am Soc Nephrol,2001,12(3):413422.

共引文献90

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部